Olezarsen vs RBD5044
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertriglyceridemia
Shared mechanism: APOC3 · full Hypertriglyceridemia pipeline
Olezarsen · Tryngolza
Marketed by Ionis Pharmaceuticals and partners
NCT05610280 · Phase 3 · completed
Essence-TIMI 73b was a large, randomized, double-blind, placebo-controlled trial in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, or with severe hypertriglyceridemia. The primary outcome was the placebo-adjusted percent change in triglycerides from baseline to 6 months in the moderate-hypertriglyceridemia population (1,349 patients). Triglycerides fell by 58.4 percentage points more than placebo with olezarsen 50 mg and by 60.6 percentage points more with 80 mg (P<0.001 for both), so the primary endpoint was met at both doses. The figures come from the peer-reviewed paper (N Engl J Med 2025).
Next expected readout: March 2027 · NCT05681351 (registry estimate)
Reported efficacy
Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)
Result source: NCT05552326
RBD5044
Developed by Suzhou Ribo Life Science and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07587788 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Hypertriglyceridemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
RBD5044: no structured comparison results are available for Hypertriglyceridemia.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olezarsen
show 7 more results
show 7 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
+ 1 further endpoint in the CSV export.
Available safety results
Olezarsen
| Dropout rate | 8.8%80 mg NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results12.1%50 mg NCT05355402 · Phase 2 · registry result, not featured evidence 0%50 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 13%15 mg Q2W NCT03385239 · Phase 2 · registry result, not featured evidence 13.6%10 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 17.4%10 mg QW NCT03385239 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —80 mg NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results—50 mg NCT05355402 · Phase 2 · registry result, not featured evidence 0%50 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 4.3%15 mg Q2W NCT03385239 · Phase 2 · registry result, not featured evidence 0%10 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 0%10 mg QW NCT03385239 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 14%80 mg NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results10.3%50 mg NCT05355402 · Phase 2 · registry result, not featured evidence 13.6%50 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 17.4%15 mg Q2W NCT03385239 · Phase 2 · registry result, not featured evidence 13.6%10 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 4.3%10 mg QW NCT03385239 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 80 mg covid-19 7% (placebo 5.1%) diabetes mellitus 7% (placebo 2.6%) acute sinusitis 5.3% (placebo 2.6%) NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results50 mg injection site erythema 13.8% (placebo 0%) fatigue 10.3% (placebo 2.6%) urinary tract infection 10.3% (placebo 15.4%) NCT05355402 · Phase 2 · registry result, not featured evidence 50 mg Q4W injection site erythema 18.2% (placebo 0%) nasopharyngitis 18.2% (placebo 12.5%) nausea 18.2% (placebo 4.2%) NCT03385239 · Phase 2 · registry result, not featured evidence 15 mg Q2W nasopharyngitis 17.4% (placebo 12.5%) arthralgia 13% (placebo 0%) dizziness 13% (placebo 0%) NCT03385239 · Phase 2 · registry result, not featured evidence 10 mg Q4W anaemia 13.6% (placebo 0%) arthralgia 13.6% (placebo 0%) back pain 13.6% (placebo 4.2%) NCT03385239 · Phase 2 · registry result, not featured evidence 10 mg QW injection site erythema 21.7% (placebo 0%) nasopharyngitis 21.7% (placebo 12.5%) upper respiratory tract infection 17.4% (placebo 12.5%) NCT03385239 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olezarsen's landscape · RBD5044's landscape